1. Home
  2. COOT vs EQ Comparison

COOT vs EQ Comparison

Compare COOT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COOT
  • EQ
  • Stock Information
  • Founded
  • COOT 2020
  • EQ 2017
  • Country
  • COOT Australia
  • EQ United States
  • Employees
  • COOT N/A
  • EQ N/A
  • Industry
  • COOT
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • COOT
  • EQ Health Care
  • Exchange
  • COOT NYSE
  • EQ Nasdaq
  • Market Cap
  • COOT 23.0M
  • EQ 24.8M
  • IPO Year
  • COOT N/A
  • EQ 2018
  • Fundamental
  • Price
  • COOT $1.18
  • EQ $0.64
  • Analyst Decision
  • COOT
  • EQ Buy
  • Analyst Count
  • COOT 0
  • EQ 2
  • Target Price
  • COOT N/A
  • EQ $5.00
  • AVG Volume (30 Days)
  • COOT 41.0K
  • EQ 141.5K
  • Earning Date
  • COOT 01-01-0001
  • EQ 11-13-2024
  • Dividend Yield
  • COOT N/A
  • EQ N/A
  • EPS Growth
  • COOT N/A
  • EQ N/A
  • EPS
  • COOT N/A
  • EQ N/A
  • Revenue
  • COOT $22,502,817.00
  • EQ $45,914,000.00
  • Revenue This Year
  • COOT N/A
  • EQ $4.76
  • Revenue Next Year
  • COOT N/A
  • EQ N/A
  • P/E Ratio
  • COOT N/A
  • EQ N/A
  • Revenue Growth
  • COOT 16.10
  • EQ 7.70
  • 52 Week Low
  • COOT $0.61
  • EQ $0.56
  • 52 Week High
  • COOT $11.96
  • EQ $3.25
  • Technical
  • Relative Strength Index (RSI)
  • COOT 52.66
  • EQ 39.10
  • Support Level
  • COOT $1.09
  • EQ $0.64
  • Resistance Level
  • COOT $1.69
  • EQ $0.73
  • Average True Range (ATR)
  • COOT 0.14
  • EQ 0.08
  • MACD
  • COOT -0.02
  • EQ -0.00
  • Stochastic Oscillator
  • COOT 19.05
  • EQ 10.12

About COOT AUSTRALIAN OILSEEDS HOLDINGS LTD

Australian Oilseeds Holdings Ltd through its subsidiaries, is focused on the manufacture and sale of chemical-free, non-GMO, sustainable edible oils and products derived from oilseeds. The company believes that transitioning from a fossil fuel economy to a renewable and chemical-free economy is the solution to many health problems the world is facing presently.

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Share on Social Networks: